Fat oxidation, lipolysis, and free fatty acid cycling in obesity-prone and obesity-resistant rats.
Defects in fat metabolism may contribute to the development of obesity, but what these defects are and where they occur in the feeding/fasting cycle are unknown. In the present study, basal fat metabolism was characterized using a high-fat diet (HFD)-induced model of obesity development. Male rats consumed a HFD (45% fat, 35% carbohydrate) ad libitum for either 1 or 5 wk (HFD1 or HFD5). After 1 wk on the HFD, rats were separated on the basis of body weight gain into obesity-prone (OP, > or =48 g) or obesity-resistant (OR, </=40 g) groups. Twenty-four-hour-fasted rats were studied either at this time (OP1, OR1) or after 5 wk (OP5, OR5). Fat pad weight (sum of epididymal, retroperitoneal, and mesenteric fat pads) at HFD1 was 26% greater and at HFD5 was 43% greater (P</=0.05) in OP vs. OR. Free fatty acid rates of appearance (FFA R(a)) and oxidation were not significantly different between OP and OR at 1 or 5 wk. Glycerol R(a), when expressed in absolute terms (micromol/min), increased from 1 to 5 wk of HFD feeding in both OP and OR, but significantly so only in OP. Likewise, increased rates of intracellular FFA cycling [estimated as (3 x glycerol R(a)) - FFA R(a)] were observed in both OP and OR rats from 1 to 5 wk of HFD feeding, but significantly so in OP rats only. When expressed relative to fat cell volume (micromol. pl(-1). min(-1)), neither lipolysis nor intracellular cycling was significantly different between OP and OR, regardless of time on HFD. These data suggest that 1) if low rates of fat oxidation contribute to obesity development in OP rats, the contribution does not occur at times when fat oxidation is at or near maximum rates (i.e., 24-h fasted conditions), and 2) between 1 and 5 wk of HFD feeding, basal lipolysis and reesterification may work to expand fat cell volume and increase fat pad weight in both OP and OR rats, although more so in OP rats.
Commerford
S R
SR
Department of Pediatrics, University of Colorado Health Sciences Center, Denver 80262, USA. Renee.Commerford@asu.edu
Pagliassotti
M J
MJ
Melby
C L
CL
Wei
Y
Y
Gayles
E C
EC
Hill
J O
JO
D017667:Adipocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002153:Calorimetry, Indirect; D002452:Cell Count; D048429:Cell Size / Q000187:drug effects; D004041:Dietary Fats / Q000378:metabolism / Q000494:pharmacology; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D004951:Esterification; D005223:Fats / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005990:Glycerol / Q000097:blood; D008066:Lipolysis / Q000502:physiology*; D008297:Male; D009638:Norepinephrine / Q000097:blood; D009765:Obesity / Q000378:metabolism*; D010084:Oxidation-Reduction; D011659:Pulmonary Gas Exchange / Q000502:physiology; D051381:Rats; D014280:Triglycerides / Q000378:metabolism
D001786:Blood Glucose; D004041:Dietary Fats; D005223:Fats; D005230:Fatty Acids, Nonesterified; D014280:Triglycerides; D005990:Glycerol; D009638:Norepinephrine